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https://doi.org/10.1016/j.jacl.2018.04.0BACKGROUND: Familial chylomicronemia syndrome (FCS) is a rare genetic disorder characterized
by a deficiency of lipoprotein lipase leading to extreme hypertriglyceridemia. Patients’ burden of
illness and quality of life have been poorly addressed in the literature.
OBJECTIVE: To understand the ways in which FCS impacts patients’ lives.
METHODS: Investigation of Findings and Observations Captured in Burden of Illness Survey (IN-
FOCUS) was a global web-based survey open to patients with FCS. Survey questions captured informa-
tion on diagnostic experience, symptoms, comorbidities, disease management, and impact on multiple life
dimensions.
RESULTS: Of 166 patients in 10 countries, 62% were from the United States and 70% were male.
Median age at the time of the survey was 33 years, and median age at diagnosis was 9 years. Patients
saw a mean of 5 physicians from different specialties before their FCS diagnosis and experienced mul-
tiple physical, emotional, and cognitive symptoms on a daily to monthly basis; 40% were admitted to the
hospital in the past year. A lifetime mean of 13 episodes occurred in the 40% of patients with FCS-related
acute pancreatitis. Most patients (.90%) found managing fat intake to be difficult, and 53% experienced
symptoms despite adherence to their diets. FCS impacted employment status (94%), emotional/mental
well-being (58%–66%), and social relationships (68%–82%).
CONCLUSIONS: Patients with FCS experience significant clinical and psychosocial burdens that
reduce their quality of life and limit employment and social interactions. Increased awareness among
healthcare professionals of the multifaceted nature of the FCS disease burden may help expedite diag-
nosis and timely institution of treatment and broaden management considerations.t of Medicine, University of Chi-
o, IL 60637, USA.
cago.edu
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Familial chylomicronemia syndrome (FCS) is a rare
genetic disorder characterized by extremely high serum
levels of triglycerides (TG), on a persistent basis, caused by
reduced or absent lipoprotein lipase (LPL) activity.1 In 80%
to 90% of patients, the function of LPL is limited or
impaired because of loss-of-function mutations in the
LPL gene encoding the LPL protein, but rarer mutations
in genes such as APOA5, APOC2, LMF1, and GPIHBP1
that encode for cofactors and transport proteins important
for adequate LPL function have also been described.1,2
LPL catalyzes the hydrolysis of plasma TG and uptake of
fatty acids into peripheral tissues such as muscle and adi-
pose tissue; in the absence of LPL activity, excessive levels
of chylomicrons accumulate in plasma, with fasting plasma
TG values usually being well in excess of 1000 mg/dL.1
Despite its rarity, FCS affects an estimated 3000 to 5000
patients globally, and its effects can be devastating and even
fatal.1 Patients with FCS present with a variety of signs and
symptoms, such as nausea, vomiting, eruptive xanthomas, li-
pemia retinalis, hepatosplenomegaly, recurrent episodes of
mild to incapacitating abdominal pain, failure to thrive,
and severe and recurrent episodes of acute pancreatitis
(AP).1,2 The complication of greatest concern is AP, which
not only may lead to chronic pancreatic functional impair-
ment after a single attack but may also be life threatening.3
Recurrent AP occurs in $50% of FCS patients; the overall
associated mortality rate is 5% to 6%, but it increases to
30% in subgroups of markedly hypertriglyceridemic patients
who experience pancreatic necrosis following an infected
pancreatic abscess or persistent multiple organ failure.2,4
The mainstays of symptom management are dietary
restriction of total fat intake, abstinence from alcohol, and
avoidance of medications known to increase TG levels, such
as thiazides, beta blockers, and exogenous estrogen.1,5,6
Lipid-lowering agents such as fibrates, omega-3 fatty acids,
and niacin are generally ineffective, primarily because they
act by reducing the hepatic output of very low-density lipo-
proteins or by enhancing LPL activity.2,5 To reduce plasma
TG levels, patients must restrict their total fat intake to no
more than 10% to 15% of calories. Adherence to dietary re-
strictions of this severity over a patient’s lifetime is difficult,
negatively impacts quality of life, and does not completely
obviate the risk for pancreatitis in all patients.2
Acute clinical manifestations of FCS, such as AP, have
been well documented, but other manifestations, such as
pain, cognitive impairment, and psychosocial effects, have
been less well described. Thorough description of these
FCS indicators could improve physician’s ability to recog-
nize the signs and symptoms of the disease, understand the
heterogeneity of the disease, and, ultimately, lead to better,more rapid disease management. The Investigation of
Findings and Observations Captured in Burden of Illness
Survey in FCS Patients (IN-FOCUS) was a multinational
web-based survey conducted to characterize and quantify
the burden of illness associated with FCS across all possible
dimensions from the patient’s perspective, add to the
literature base of FCS, and inform more comprehensive
description of FCS for the medical community. The survey
collected data on initial experience with FCS, diagnosis,
symptoms, comorbidities, management, and impact on
different dimensions of life. Findings from an interim
analysis of this study based on 60 patients from the United
States have been published.7 That initial report highlighted
the difficulty of diagnosing FCS, its multiplicity of symp-
toms and comorbidities, its impact on patients’ physical,
emotional, and cognitive functioning, and its interference
with patients’ employment and productivity. The current
report, which presents an updated analysis from IN-
FOCUS, expands on the interim analysis to characterize
the burden of illness in a larger global cohort.Patients and methods
Study design
IN-FOCUS was an online, anonymous, quantitative
research study consisting of a web-based survey, conducted
in patients with diagnoses of FCS. The study design and
patient selection have been detailed elsewhere7 and are sum-
marized here. All research materials were approved by the
institutional review board of the University of Mississippi.
Data from the web-based survey were collected from
respondents in 10 countries (Australia, Canada, Germany,
India, Netherlands, Portugal, Spain, Sweden, United
Kingdom, and United States) between June 24, 2016, and
February 24, 2017. It was designed to capture current and
retrospective data about the experience of living with FCS
as self-reported by eligible patients with FCS. Survey
questions were derived from established patient-reported
outcomes assessments, including the Short-Form 36 Health
Survey and the Pancreatitis Quality of Life Instrument, and
from consultation with expert physicians, dieticians, and
patients. A sampling of questions from the survey is shown
in Supplementary Figure S1.
Patients
Patients were recruited through flyers, word of mouth,
and social media outlets. Physicians with experience
treating FCS were provided with informational flyers to
share with eligible or interested patients. Patients
Table 1 Baseline demographics and characteristics
Patient characteristics
Patients
(n 5 166)
Sex (male) 116 (69.9)
Age at time of survey, y
Median (range) 33 (18–59)
0–10 0 (0)
11–20 8 (4.8)
21–30 69 (41.6)
31–40 46 (27.7)
41–50 30 (18.1)
51–60 13 (7.8)
Age at FCS diagnosis, y
Median (range) 9 (1–57)
0–10 121 (72.9)
11–20 28 (16.9)
21–30 5 (3.0)
31–40 5 (3.0)
41–50 5 (3.0)
51–60 2 (1.2)
Country of residence
United States 103 (62.0)
Canada 37 (22.3)
Australia 9 (5.4)
United Kingdom 9 (5.4)
Germany 2 (1.2)
Sweden 2 (1.2)
India 1 (0.6)
Netherlands 1 (0.6)
Portugal 1 (0.6)
Spain 1 (0.6)
Family history of FCS
Yes 119 (72)
No. of physicians seen before diagnosis, n
Mean 5
1–3 37
4–6 85
7–9 1
$10 8
Physician who made the diagnosis
Endocrinologist 34 (20)
Pancreatologist 20 (12)
Pediatrician 16 (10)
Lipidologist 10 (6)
Cardiologist 6 (4)
Primary care physician 6 (4)
Metabolic specialist 6 (4)
Nephrologist 4 (2)
Dermatologist 3 (2)
Surgeon 1 (1)
Other 6 (4)
Unable to recall 54 (33)
Patients with genetically confirmed diagnosis 10 (6)
Patients with misdiagnoses 79 (48)
Most common misdiagnoses
Hypertriglyceridemia 37 (47)
Acute pancreatitis of unknown cause 33 (42)
FCS, familial chylomicronemia syndrome.
Values are n (%) unless stated otherwise.
Davidson et al Burden of disease in patients with FCS 3completed a series of screening questions online to
determine their eligibility to participate.
Eligible patients met the following criteria: $18 years
of age, diagnosis of FCS or Fredrickson type 1 Hyperlipo-
proteinemia or LPL deficiency or high TG level with a his-
tory of pancreatitis or high TG level with a history of severe
abdominal pain requiring hospital admission, fasting TG
level $750 mg/dL (8.4 mmol/L) determined by the most
recent fasting TG test or fasting TG level ,750 mg/dL
determined by the most recent fasting TG test with self-
reported diet management to minimize fat content, and no
participation in a clinical trial for FCS investigational treat-
ment(s) in the previous 6 months. In addition, 1 of the
following 4 criteria had to be met: personal history of
TG-induced AP in the absence of another known cause, his-
tory of recurrent abdominal pain requiring emergency
department visit/hospital admission attributed to high TG
levels in the absence of another known cause, family his-
tory compatible with FCS or Fredrickson type 1 Hyperlipo-
proteinemia in the absence of another known cause, or
genetic diagnosis consistent with FCS.
Statistical analysis
The final data cutoff date for these analyses was
February 24, 2017. Complete data are presented for all
cohorts except that from the United Kingdom, which
continued to accrue patients after the data cutoff date.
Categorical variables were analyzed descriptively as fre-
quencies and percentages of occurrence for each category.
Continuous variables, including rating scales, were pre-
sented as means and standard deviations or as medians with
ranges. Analyses were conducted using SPSS Statistics 22
(IBS, Armonk, NY).Results
Patient sample
A total of 600 patients were screened (answered $1
question); of the 217 patients who qualified, 166 completed
the questionnaire. Demographic and baseline characteristics
of respondents are summarized in Table 1. Most respondents
were from the United States (62.0%) and Canada (22.3%),
and 70% of the population was male. Median (range) age
of respondents was 33 years (18–59 years), and median
(range) age at FCS diagnosis was 9 years (1–57 years).
The diagnosis was made in nearly three-fourths of patients
(72.9%) by the time they were 10 years of age.
Journey to FCS diagnosis
Patients were seen by a mean of 5 physicians before a
diagnosis of FCS was made (Table 1). However, 8 patients
reported visiting $10 physicians, and 1 patient visited up
4 Journal of Clinical Lipidology, Vol -, No -, - 2018to 30 physicians. The most common specialists to make the
FCS diagnosis were endocrinologists, pancreatologists, and
pediatricians. Misdiagnoses were common; 79 patients
(48%) reported receiving a misdiagnosis before receiving a
correct diagnosis. FCS was most commonly misdiagnosed
as hypertriglyceridemia (47%) and AP of unknown cause
(42%).
Symptoms
A list of 41 symptoms encompassing physical, emotional,
and cognitive domains associated with FCS was developed
through consultation with the published literature, medical
experts, and patients. Patients rated the severity and frequency
of symptoms on a Likert scale (range, 1–7; 1 5 very mild,
75 very severe) for the preceding 12 months.
The incidence, frequency, and severity at which patients
experienced physical, emotional, and cognitive symptoms
at their highest severity are shown in Figures 1–3, respec-
tively. The size of each sphere on the figures reflects the
rate at which each symptom was reported. The most
commonly reported physical symptoms were generalized
abdominal pain (41%), bloating (37%), feeling of physical
weakness (asthenia, 30%), indigestion (27%), and fatigue
(23%) (Table 2). In general, patients reported experiencing
these symptoms twice a week to once every 2 weeks
(Fig. 1). The 4 most common emotional symptoms were
constant uncertainty about the possibility of an attack of
AP or pain at any time (34%), anxiety/fear/worry about1.0
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how much to eat (20%), and feeling out of control/helpless
because of FCS (17%) (Table 2). Patients experienced these
symptoms several times a week to once monthly (Fig. 2).
Cognitive symptoms included difficulty in concentrating
(16%), impaired judgment (11%), brain fog (8%), and
forgetfulness (8%); patients experienced these symptoms
daily or every other day (Fig. 3).
In general, sex differences were not observed in a
majority of physical and emotional symptoms experienced
by patients (Supplementary Table S1). However, there was
a greater prevalence of selected physical and cognitive dif-
ferences of FCS symptoms reported in females compared to
males, including steatorrhea (22% vs 9%), difficulty in
hearing (10% vs 2%), anxiety in food-related social situa-
tions (26% vs 13%), impaired judgement (22% vs 7%),
and brain fog (16% vs 5%).
Comorbid conditions
Patients with FCS often have multiple comorbidities. At
least one-third of the patients reported 2 or more comor-
bidities, including AP (40%), eating disorders (23%),
diabetes (16%), chronic pancreatitis (11%), hepatomegaly
(11%), splenomegaly (10%), hypertension (10%), lipemia
retinalis (9%), peripheral neuropathy (7%), addiction to
pain medication such as opioids (5%), other conditions
(5%), and pancreatic calcification (2%) (data not shown).
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Figure 2 Emotional symptoms at their worst or most severe. For each symptom selected, patients indicated symptom severity and fre-
quency. Severity was recorded on a Likert scale (range, 1–7; 15 very mild, 75 very severe). Frequency was recorded by selection from the
following options: multiple times per day, daily, every other day, twice a week, once a week, or every other week. Sphere size in the chart is
proportional to the percentage of patients who selected each symptom.
1.0
2.0
3.0
4.0
5.0
6.0
7.0
0 1 2 3 4 5 6 7 8
Av
er
ag
e 
Sy
m
pt
om
 S
ev
er
ity
Multiple
times per 
day
Daily Every
other day
2x/week 1x/week Every other 
week
1x/month
Median Symptom Frequency
Figure 3 Cognitive symptoms at their worst or most severe. For each symptom selected, patients indicated symptom severity and fre-
quency. Severity was recorded on a Likert scale (range, 1–7; 1 5 very mild, 7 5 very severe). Frequency was recorded by selection
from the following options: multiple times per day, daily, every other day, twice a week, once a week, or every other week. Sphere size
in the chart is proportional to the percentage of patients who selected each symptom.
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6 Journal of Clinical Lipidology, Vol -, No -, - 2018FCS visited their doctors 7 times (routine visits), urgent
care 2 times, hospital as outpatient 3 times, and hospital as
inpatient 1 time (hospital stay, 4 nights) and underwent
laboratory tests on a monthly basis (data not shown).
Forty percent of patients with FCS experienced $1
episode of AP; a mean of 2 episodes occurred in the past
12 months, and 13 episodes occurred in their lifetimes
(Fig. 4). These patients visited the hospital as outpatients
5 times and as inpatients 6 times in their lifetimes.
Approximately 50% of patients reported that they visited
the hospital (as inpatients or outpatients) for every AP
episode, and approximately 25% reported that they had
been readmitted to the hospital within 30 days of
discharge.Table 2 Frequency of symptoms when most severe: physical, emoti
Physical, % (21 symptoms) Emotional, % (13
Generalized
abdominal pain
41 Back pain 16 Constant
uncertainty
about having a
attack of pain
acute
pancreatitis at
any time
Bloating 37 Numbness or
tingling of digits
14 A/F/W about heal
due to FCS
Asthenia 30 Headaches 14 A/F/W about
having to plan
what or how
much to eat
Indigestion 27 Steatorrhea 13 Embarrassment
about always
thinking about
and planning f
my food
Lack of appetite 25 Excessive sweating 11 Feeling sad/down
blue/depressed
Fatigue 23 Jaundice 10 A/F/W about
triggering
symptom flare
eating food
prepared by
someone else
Joint pain 22 Cold sensations 9 A/F/W in social
situations (foo
related)
Pancreatic pain 19 Nausea/vomiting 8
Feeling cold all the
time in
extremities
18 Skin changes
resembling
sunburn
8
Flatulence 18 Respiratory
problems/
dyspnea
4
Xanthoma 17
A/F/W, anxiety/fear/worry; FCS, familial chylomicronemia syndrome.Disease management
Patients reported using a median of 6 different strategies to
manage FCS. Most patients (91%) managed their disease by
restricting fat intake, but one-third practiced routine fasting to
avoid symptoms (Fig. 5). In addition,.50% of patients used
TG-lowering medication or avoided alcohol or drugs known
to increase TG levels. Most patients reported that managing
their symptoms was extremely time-consuming (81%) and
energy-draining (70%), and their approach was rigid/prohibi-
tive (Supplementary Fig. S2). Although approximately two-
thirds of patients (67%) reported that their current approach
was effective, 53% experienced symptoms despite adherence
to their diets.onal, and cognitive
symptoms) Cognitive, % (7 symptoms)
n
or
34 Feeling out of
control/
powerless
because of my
FCS
17 Difficulty
concentrating
16
th 26 Anger/frustration
with having FCS
17 Impaired judgment 11
20 A/F/W in social
situations
(nonfood
related)
15 Brain fog 8
or
20 Social withdrawal/
feeling isolated
13 Forgetfulness 8
/ 18 Feeling
misunderstood/
not understood
11 Difficulty
understanding what
others are saying
5
by
18 A/F/W around
having to get
regular testing
for my FCS
11 Recent memory loss 5
d
17 Difficulty hearing 4
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Figure 4 Number of acute pancreatitis episodes experienced by
patients with FCS, who reported acute pancreatitis as a comorbid-
ity. (A) Past 12 months. (B) Lifetime.
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population is 44 g to 78 g.8 Most patients tried to limit their
daily fat intake to 18 g to 25 g (equivalent to fat content of
approximately 1–1.5 tbsp olive oil), but doing so was diffi-
cult for 93% of patients (Supplementary Fig. S2). When
they exceeded the recommended dietary fat limit, patients
most commonly reported feeling fearful, annoyed, anxious,
helpless, or sick/ill (Supplementary Fig. S3).
In general, although patients were satisfied with their
current treatment providers, they were less satisfied with their
historical experience with FCS professionals (Supplementary
Fig. S4). The proportion of patients who trusted their medical
professionals to treat their condition properly andwho felt they
were more knowledgeable about their condition than most
physicians were similar (46% and 45%, respectively). Be-
tween 26% and 45% of patients felt that somemedical profes-
sionals did not understand their disease, made them feel guilty
or responsible for their symptoms, gave advice that would
have worsened symptoms, or seemed unsympathetic.
Impact of FCS on patients’ employment and
personal and social well-being
Thirty-two percent of patients reported that FCS signifi-
cantly interfered with their lives (Fig. 6). Sixty percent ofpatients with FCS were employed full time or part time;
among those who were unemployed or employed part time,
94% felt that their employment status was due, by varying
extent, to FCS (Supplementary Fig. S5). Most of those who
were unemployed (76%) had been employed in the past, and
65% of this group attributed their unemployment to FCS.
Among homemakers, 40% felt their lack of employment op-
portunities was due to FCS.
When questioned about their relationships and social
activities, patients said the greatest negative impacts of FCS
were on their ability to travel for work or leisure (48%) and
on whether to have children at all or on how many children
to have (44%) (Fig. 7). Approximately 75% of respondents
felt their social lives were restricted because of the need to
plan in advance for food, stress from having to carry pre-
pared food, not eating or not being able to share offered
food, stress on their families, difficulty friends and families
experienced in trying to understand FCS, exhaustion
because of constantly having to explain FCS, difficulty be-
ing spontaneous, and feeling like a burden to others
(Supplementary Fig. S6). By contrast, 70% of respondents
reported that FCS strengthened their relationship with their
spouse (Supplementary Fig. S7).
The mental and emotional well-being of nearly two-
thirds of patients was significantly affected by FCS,
particularly with respect to anxiety and feelings of self-
worth (Supplementary Fig. S8). Most patients (71%–87%)
expressed concern about the potential long-term impact of
FCS on their health and other aspects of their lives,
including worsening of their condition with age, long-
term effects of FCS on health, ability to lead a normal
life, and losing their jobs or becoming unable to work
because of FCS (Supplementary Fig. S9).Discussion
This report of the global IN-FOCUS study outlines the
burden of FCS and the challenges associated with man-
aging this disease throughout a patient’s lifetime by
providing a comprehensive inventory of the factors under-
lying the disease burden. These results highlight the
difficulty of obtaining a correct diagnosis, the clinical
burden of a disease with frequent and painful symptoms
that often lead to hospital admission, and the limitations on
employment and overall social and emotional function.
This study expands on the interim report and on study-
based patient interviews and discussions, all of which
highlight the multidimensional impact of FCS on quality
of life.7,9 Furthermore, this report highlights the fact that
FCS manifests itself not only through physical disease
characteristics, including AP, but also describes the
emotional, social, and cognitive symptoms many patients
with FCS experience as a precursor to, or independent
from, AP and other physical manifestations. This detailed
report on the disease burden of FCS has the potential to
impact the journey to diagnosis and to expedite the
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Figure 5 Management strategies used by patients with FCS. Response percentages may total .100% because respondents may use .1
strategy.
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ease management.
As in the interim analysis,7 patients in this study visited
a mean of 5 physicians (range, 1–30) before receiving a
definitive diagnosis of FCS, suggesting a potential delay
in receiving appropriate care. The high frequency of both
misdiagnosis and appropriate diagnosis from different med-
ical specialists indicates a lack of awareness of FCS among
medical practitioners and a need for stronger educational
initiatives. Delay in diagnosis is a particular issue in rare
diseases because it results in delayed treatment, increased
morbidity, and potentially life-threatening complica-
tions.10,11 The cycling of patients through multiple
providers and sometimes extensive and repetitive testing
and the possibility of conflicting recommendations for
treatment may worsen symptoms and increase the psycho-
logical and emotional burden for patients.110% 1%
7% 22% 3
0% 10% 20% 30% 40%
Interference
Pat
1 (No Interference At All) 2 3
Figure 6 Overall interferenceThe emotional burden on patients is related to their
uncertainty about the next attack of pain or AP, need for a
highly restrictive diet, and search for a knowledgeable and
empathetic physician. Managing the lifestyle events
involved in such a restricted fat intake is draining and
time consuming for almost all patients and can be
associated with fear, anxiety, helplessness, and guilt
when dietary fat limits are exceeded. Although FCS is
usually diagnosed when patients are young, and they
become accustomed to their symptom burden, diet, and
lifestyle modifications over the years, they often experi-
ence lower quality of life than persons without FCS.
Comorbid conditions can add to the physical and
emotional burden imposed on patients with FCS. Physi-
cians can better manage FCS if they have a better
understanding of the nature and extent of common
comorbid conditions.9% 24% 8%
50% 60% 70% 80% 90% 100%
ients (%)
4 5 6 7 (Significant Interference)
of FCS with patients’ life.
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Figure 7 Impact of FCS on social relationships and activities.
Davidson et al Burden of disease in patients with FCS 9Although the patients surveyed said they were generally
satisfied with their current providers, almost one-third to
one-half considered themselves more knowledgeable than
their medical professionals, most likely because physicians
are not familiar with the strict dietary fat restrictions
needed for effective control. Moreover, patients reported
a lack of understanding and sympathy and said they
received conflicting or incorrect advice from providers.
This underscores the importance of a detailed report of the
FCS manifestations beyond the physical manifestations
described in the extant literature. Much of the mental and
emotional burden for these patients stemmed from the
difficulty of following a strict diet and living with the
constant fear and anxiety that they could experience
symptoms despite that diet. Nearly two-thirds of patients
stated that FCS interfered significantly with their self-
worth, emotional well-being, sleep, and mental functioning.
In addition, a large majority of patients were not optimistic
about the future and were worried about their condition
worsening, long-term health effects, potential job loss, and
ability to live a normal life. The impact of FCS on
employment was shown in the interim results7 and was
corroborated here in the global sample.
Although these results provide a window into the true
burden of FCS, several limitations should be considered
based on the study design. Because the findings were self-
reported, independent verification of facts and experiences is
not possible. For example, patients with secondary hyper-
triglyceridemia (eg, diabetes related) could not be excluded.
In addition, this study was not longitudinal, which meant the
evolution of symptoms over time and with longer diseaseexperience could not be evaluated. The fact that the survey
was administered online suggests the potential for selection
bias favoring younger patients, more digitally knowledge-
able patients, or sicker patients who are more engaged with
their disease and willing to take the time to participate.
Selection bias may be one of the factors limiting the general
applicability of the results of the survey because of the
nonrepresentative nature of the internet population and the
self-selection bias of the respondents. Because recruitment
was conducted primarily by word of mouth and by referrals
within FCS patient groups and organizations, this study
sample may represent only a subset of the FCS population.
Finally, because the study lacks a comparator group, such as
a group of patients with a different rare disease, it was not
possible to dissect which symptoms are specific to patients
with FCS. Secondary analyses are required to determine
whether there are groups of patients who experience worse
manifestations and whether any clustering of symptoms may
predict a prognostic pathway.
In conclusion, this study of 166 patients—the largest to
examine the burden of illness in FCS—reflects the patient
perspective on the burden FCS places on patients’ lives. By
characterizing the effect of FCS on multiple dimensions of
patients’ lives, these findings provide a comprehensive and
accurate picture of the wide-ranging ramifications of the
disease. These results highlight the need not only for more
effective treatments but also for broader clinical manage-
ment considerations for these heterogeneous symptoms.
This work should contribute to increased awareness among
health care providers about the burden of symptoms
associated with FCS, help improve current diagnosis and
10 Journal of Clinical Lipidology, Vol -, No -, - 2018management of FCS, and spur the development of more
effective treatment options.
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Physical, % (21 symptoms) Emotional, % (13 symptoms) Cognitive, % (7 symptoms)
Male
Generalized abdominal
pain
41Back pain 13Constant uncertainty
about having an
attack of pain
or acute
pancreatitis at
any time
35Feeling out of
control/powerless
because of my FCS
16Difficulty
concentrating
16
Bloating 34Numbness
or tingling
of digits*
9A/F/W about health
due to FCS*
21Anger/frustration
with having FCS
16Impaired
judgement*
7
Asthenia 28Headaches 12A/F/W about having
to plan what or how
much to eat
17A/F/W in social
situations
(nonfood related)
13Brain fog* 5
Indigestion 28Steatorrhea* 9Embarrassment about
always thinking
about and planning
for my food
17Social withdrawal/
feeling isolated
10Forgetfulness 5
Lack of appetite 26Excessive
sweating
9Feeling sad/down/blue/
depressed
17Feeling misunderstood/
not understood
9Difficulty
understanding
what others
are saying
5
Fatigue 21Jaundice 8A/F/W about triggering
symptom flare
by eating food
prepared by someone
else
16A/F/W around having
to get regular
testing for my FCS
9Recent
memory loss
3
Joint pain 19Cold
sensations
7A/F/W in social
situations
(food related)*
13 Difficulty
hearing*
2
Pancreatic pain 18Nausea/Vomiting 6
Feeling cold all the
time in extremities*
14Skin changes
resembling sunburn
9
Flatulence 18Respiratory
problems/dyspnea
3
Xanthoma 17
Female
Generalized abdominal
pain
40Back pain 22Constant uncertainty
about having an
attack of pain or
acute pancreatitis
at any time
30Feeling out of
control/powerless
because of my FCS
20Difficulty
concentrating
18
Bloating 46Numbness or
tingling of digits*
26A/F/W about health
due to FCS*
38Anger/frustration
with having FCS
18Impaired
judgement*
22
Asthenia 32Headaches 16A/F/W about having
to plan what or how
much to eat
28A/F/W in social
situations (nonfood
related)
20Brain fog* 16
Indigestion 24Steatorrhea* 22Embarrassment about
always thinking
about and planning
for my food
26Social withdrawal/
feeling isolated
18Forgetfulness 14
Lack of appetite 22Excessive
sweating
14Feeling sad/down
/blue/depressed
20Feeling misunderstood/
not understood
16Difficulty
understanding
what others are
saying
6
(continued on next page)
Supplementary Table S1 (continued )
Physical, % (21 symptoms) Emotional, % (13 symptoms) Cognitive, % (7 symptoms)
Fatigue 28Jaundice 16A/F/W about
triggering symptom
flare by eating food
prepared by
someone else
24A/F/W around having
to get regular testing
for my FCS
14Recent
memory loss
8
Joint pain 28Cold sensations 14A/F/W in social
situations
(food related)*
26 Difficulty
hearing*
10
Pancreatic pain 22Nausea/Vomiting 12
Feeling cold all the
time in extremities*
28Skin changes
resembling sunburn
4
Flatulence 18Respiratory
problems/dyspnea
6
Xanthoma 18
*Indicates significant difference in proportion of respondents between genders at 95% CI.
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